Adam Howard
Papers
1
Total Citations
30
H-Index
1
About
Adam Howard is a leading clinical researcher in head and neck oncology, specializing in the treatment of human papillomavirus-associated oropharyngeal cancer (HPV+ OPC). His major contributions center on developing innovative, de-escalation strategies that reduce treatment toxicity without compromising survival. Howard is best known for the landmark OPTIMA II trial, which pioneered a novel approach combining nivolumab (an anti-PD-1 immunotherapy) with nab-paclitaxel and carboplatin as induction therapy, followed by risk- and response-adapted locoregional treatment. This work, cited over 30 times, demonstrated that immunotherapy can be safely integrated into curative-intent regimens, allowing many patients to avoid high-dose cisplatin and its severe side effects. By leveraging the favorable prognosis of HPV+ OPC, Howard’s research has reshaped clinical paradigms toward personalized, less morbid care. His achievements include advancing the field’s understanding of how to use immune checkpoint inhibitors in the neoadjuvant setting, a critical step toward reducing long-term treatment burden. With a growing citation impact, Adam Howard is a pivotal figure in the movement toward precision de-escalation in head and neck cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1